Key insights
- BD (BDX) launched the Elyra Thulium Fiber Laser System for urologic procedures. The company also reported Q2 2026 earnings that surpassed analyst expectations. While positive for BD, the news has a limited bullish influence on the broader US equity market.
FRANKLIN LAKES, N.J. - BD (NYSE:BDX) announced today the introduction of the Elyra Thulium Fiber Laser System for urologic stone management and soft tissue procedures, according to a company press release.
The system uses Thulium Fiber Laser technology and features an air-cooled design. BD offers the platform in two configurations, Elyra and Elyra Plus, to accommodate different operational requirements.
The system includes an intuitive user interface, quick startup capabilities, customizable presets, and an optional wireless footswitch available with the Elyra Plus model. The air-cooled design provides a smaller footprint compared to traditional laser systems.
"Elyra demonstrates how BD innovates with speed and purpose, introducing technology that helps clinicians deliver high-quality care more efficiently," said Mike Cusack, worldwide president of Urology and Critical Care at BD.
BD completed initial clinical cases using the Elyra Plus system at a medical center, where urologists and laser technicians provided feedback on the interface and safety features.
The Elyra and Elyra Plus systems are now available in the United States. The platform adds to BD’s urologic stone management portfolio, which includes products for access, dilation, visualization, fragmentation, removal and drainage.
BD is a medical technology company with more than 60,000 employees operating globally. With a market capitalization of $40.4 billion and a P/E ratio of 25.4, the company stands as a prominent player in the Healthcare Equipment & Supplies industry, according to InvestingPro data. The stock currently appears undervalued based on InvestingPro’s Fair Value analysis. Investors can access detailed insights through BD’s comprehensive Pro Research Report, one of 1,400+ available for top US equities.
In other recent news, Becton Dickinson reported its Q2 2026 earnings, surpassing analyst expectations with an adjusted earnings per share (EPS) of $2.90, compared to the projected $2.78. The company’s revenue reached $4.7 billion, slightly exceeding the anticipated $4.67 billion. In addition to the earnings announcement, Becton Dickinson Euro Finance S.à r.l., a subsidiary of Becton Dickinson, successfully completed an underwritten public offering of €600 million in notes due 2033. These notes, carrying an interest rate of 3.855%, are fully guaranteed by Becton Dickinson.
Furthermore, Becton Dickinson announced the appointment of Peter Menziuso as the executive vice president and president of BD Interventional, effective June 1. Menziuso previously held the position of Company Group Chairman at Johnson & Johnson Vision. These developments reflect Becton Dickinson’s ongoing strategic initiatives and financial activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.